Can Fite Biopharma Ltd ADR Total Assets
Can Fite Biopharma Ltd ADR total assets. Based on the latest financial reports, Can Fite Biopharma Ltd ADR (CANF) holds total assets worth $9.51 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Can Fite Biopharma Ltd ADR (CANF) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Can Fite Biopharma Ltd ADR (2011–2025)
Total assets of Can Fite Biopharma Ltd ADR from 2011 to 2025. This chart illustrates how Can Fite Biopharma Ltd ADR's total assets have evolved over time, based on quarterly financial data. See CANF stock price for real-time trading data and today's change.
Can Fite Biopharma Ltd ADR - Asset Composition Analysis
Can Fite Biopharma Ltd ADR Total Assets Breakdown (December 2025)
Can Fite Biopharma Ltd ADR total assets breakdown as of December 2025. Can Fite Biopharma Ltd ADR's total assets of $9.51 Million consist of 99.2% current assets and 0.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 58.1% |
| Accounts Receivable | $74.00K | 0.8% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Can Fite Biopharma Ltd ADR's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore CANF net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Can Fite Biopharma Ltd ADR's current assets represent 99.2% of total assets in 2025, an increase from 98.5% in 2011.
- Cash Position: Cash and equivalents constituted 58.1% of total assets in 2025, down from 78.4% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 0.8% of total assets.
Can Fite Biopharma Ltd ADR Competitors by Total Assets
Key competitors of Can Fite Biopharma Ltd ADR based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩12.65 Trillion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Immunovant Inc
NASDAQ:IMVT
|
USA | $852.49 Million |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
USA | $949.87 Million |
Can Fite Biopharma Ltd ADR - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.46 | 4.38 | 7.41 |
| Quick Ratio | 3.46 | 4.38 | 6.65 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $6.71 Million | $6.93 Million | $8.13 Million |
Can Fite Biopharma Ltd ADR - Advanced Valuation Insights
This section examines the relationship between Can Fite Biopharma Ltd ADR's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.34 |
| Latest Market Cap to Assets Ratio | 0.66 |
| Asset Growth Rate (YoY) | 4.3% |
| Total Assets | $9.51 Million |
| Market Capitalization | $6.23 Million USD |
Valuation Analysis
Below Book Valuation: The market values Can Fite Biopharma Ltd ADR's assets below their book value (0.66x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Can Fite Biopharma Ltd ADR's assets grew by 4.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Can Fite Biopharma Ltd ADR (2011–2025)
The table below shows the annual total assets of Can Fite Biopharma Ltd ADR from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $9.51 Million | +4.32% |
| 2024-12-31 | $9.12 Million | -8.70% |
| 2023-12-31 | $9.99 Million | +7.61% |
| 2022-12-31 | $9.28 Million | -54.16% |
| 2021-12-31 | $20.25 Million | +112.67% |
| 2020-12-31 | $9.52 Million | +16.50% |
| 2019-12-31 | $8.17 Million | +2.79% |
| 2018-12-31 | $7.95 Million | +1.53% |
| 2017-12-31 | $7.83 Million | -22.96% |
| 2016-12-31 | $10.17 Million | -42.24% |
| 2015-12-31 | $17.60 Million | +72.78% |
| 2014-12-31 | $10.19 Million | +53.54% |
| 2013-12-31 | $6.63 Million | +305.74% |
| 2012-12-31 | $1.64 Million | -66.65% |
| 2011-12-31 | $4.90 Million | -- |
About Can Fite Biopharma Ltd ADR
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase … Read more